Intercell starts a Phase I clinical trial for a new Streptococcus pneumoniae vaccine
Study aims to obtain safety and immunogenicity data of this new vaccine candidate
08-Apr-2009 -
Intercell AG announced that a Phase I clinical trial with the compan's vaccine candidate IC47 to prevent disease caused by the bacterium Streptococcus pneumoniae has started.
Intercell's vaccine candidate is a recombinant subunit vaccine consisting of three conserved surface proteins from ...
clinical trials
immunogenicity
Intercell
+3